Valence ロゴ
人気
ログイン

ウォッチリストに追加

X4 Pharmaceuticals Inc.

NasdaqCM: XFOR · リアルタイム株価 · USD
4.00
-0.16 (-3.85%)
終値時点： Aug 19, 2026, 3:59 PM

X4 Pharmaceuticals Inc. (XFOR) Stock Price, Analysis & Data

-3.85%
買気配2.96
時価総額397.08M
売上高（TTM）15.85M
純利益（TTM）-90.14M
ベータ0.39
EPS（TTM）1.43
PER（TTM）2.8
予想PER-5.3
PBR（TTM）2.48
PSR（TTM）25.06
Earnings DateNov 5, 2026
売気配4.1
出来高239,834
平均出来高（20日）752,333
始値4.12
前日終値4.16
当日レンジ3.99 - 4.22
52週レンジ2.71 - 4.83
アナリストStrong Buy
目標株価12 (200.00%)
配当n/a
権利落ち日n/a

XFORについて

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agre...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Nov 16, 2017
従業員数 45
上場取引所 NasdaqCM
ティッカー XFOR
ウェブサイト https://www.x4pharma.com
企業情報の全文

業績

2025年のX4 Pharmaceuticalsの売上高は35.11Mで、前年の2.56Mから1,273.21%の増加でした。 利益は-79.2Mで、111.48%の増加でした。

財務諸表

アナリスト予想

5件のアナリスト評価によると、XFOR株の平均レーティングは「Strong Buy」です。12か月後の目標株価は12で、直近株価から200%の上昇余地となります。

株価予想

決算サプライズ

X4 PharmaceuticalsはAug 6, 2026に四半期決算を発表しました：
  • 売上高は $8.81M で、予想を下回りました $0, うち 346.33% の前年比増加にあたります.
  • EPSは -0.13 で、予想を上回りました 0.05, うち 96.25% の前年比増加にあたります.

    • 次回決算発表

    X4 Pharmaceuticals Inc.の決算発表予定日は Nov 5, 2026, 取引時間中の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    1週間前 · Zacks

    X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

    X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    1週間前 · Zacks

    X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

    X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    2週間前 · Zacks

    Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

    Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    3か月前 · Simply Wall St.

    How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress

    X4 Pharmaceuticals has seen its modeled fair value price target move from US$8.00 to US$11.67, a sizable uplift that puts more focus on what the current share price is really discounting. Analysts are...

    news image

    3か月前 · Zacks

    Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

    X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could...

    2ページ中1ページ